View Older Stories
-
Danaher (DHR) PT Raised to $254 at Evercore ISI
-
Danaher (DHR) PT Raised to $270 at BofA Securities
-
Increasing unusual put option volume: LRN BRBR APH GOSS IAG EAT GLW LWLG STZ XRX LOGI NXT DHR AQST
-
Danaher beats Q4 expectations as bioprocessing business shows strength
-
Danaher (DHR) Tops Q4 EPS by 9c; offers outlook
-
Danaher (DHR) call put ratio 1 call to 1.2 puts into quarter results
-
Danaher expects mid-single digit revenue growth in fourth quarter
-
KeyBanc: 'We Highlight Danaher (DHR) Potential and EBITDA Upside'
-
Goldman Sachs starts Life Sciences Tools coverage, rates these 3 stocks at Buy
-
Goldman Sachs Starts Danaher (DHR) at Buy
-
KeyBanc on Life Sciences Tools & Services: 'We Highlight Our Favored 2026 "Tools" Stocks'
-
Danaher (DHR) call put ratio 1 call to 2.9 puts
-
Morgan Stanley Starts Danaher (DHR) at Overweight, Top Pick
-
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Danaher Corporation (DHR) as Securities Fraud Class Action Survives Motion to Dismiss
-
Danaher (DHR) PT Raised to $260 at TD Cowen
-
Danaher (DHR) Tops Q3 EPS by 17c
-
Danaher (DHR) call put ratio 1 call to 1.3 puts into quarter results
-
Rothschild Redburn Downgrades Danaher (DHR) to Neutral
-
KeyBanc Takeaways from This Year's BioProcess International Conference
-
Danaher authorizes buyback of up to 35 million shares
-
Stifel Reiterates Buy Rating on Danaher (DHR)
-
Danaher (DHR) Tops Q2 EPS by 16c; lifts FY EPS forecast
-
Danaher (DHR) call put ratio 1 call to 1 put into the expected release of results
-
Danaher (DHR) PT Raised to $226 at Baird, 'see potential upside in Biotechnology and Diagnostic'
-
Scotiabank Upgrades Danaher (DHR) to Sector Outperform
-
Supreme Court Braidwood ruling is positive for DX names like DHR, EXAS, NTRA, HOLX, QDEL - RBC Capital
-
Danaher (DHR) Appoints Martin Stumpe as Chief Technology and AI Officer
-
Danaher (DHR) appoints Greg Milosevich to EVP, Life Sciences
-
Askeladden Capital Shares Primary Research with AstroNova Shareholders
-
Danaher (DHR) Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine
-
Citi names 3 stocks as its new top picks in the Life Science sector
-
Askeladden Capital Presents Plan To Maximize AstroNova's Shareholder Value
-
Stifel Reiterates Buy Rating on Danaher (DHR)
-
Danaher (DHR) PT Raised to $248 at TD Cowen as '1Q Strikes Many Positive Chords'
-
Danaher (DHR) PT Raised to $215 at Barclays
-
Danaher (DHR) PT Lowered to $260 at JPMorgan
-
Danaher (DHR) PT Lowered to $230 at Jefferies
-
Danaher (DHR) Tops Q1 EPS by 26c; initiates guidance
-
Danaher (DHR) call put ratio 1.8 calls to 1 put into quarter results
-
Danaher (DHR) Danaher (NYSE: DHR) call put ratio 1 call to 1.4 puts into quarter results
-
Barclays Upgrades Danaher (DHR) to Overweight
-
TD Cowen: 'Danaher (DHR) Is Our Top Idea'; PT Lowered to $240
-
Evercore Adds 7 Names to Tactical Outperform List
-
Goldman Sachs Upgrades Danaher (DHR) to Buy
-
Stifel Upgrades Danaher (DHR) to Buy
-
TD Cowen: 'Top 10 Themes Coming Out of 45th Annual Health Care Conference'
-
Citi Opens 90-Day Upside Short-Term View on Danaher (DHR)
-
TD Cowen Issues Stock Conclusions Following Bioproduction Market Survey
-
Danaher (DHR) Appoints Charles Lamanna to its Board
-
Danaher (DHR) Declares $0.32 Quarterly Dividend; 0.6% Yield

